SlideShare uma empresa Scribd logo
1 de 50
Baixar para ler offline
TB Burden Updates:
Global and Indian Scenario
Countries in the three TB high burden
country list
Global TB Report WHO 2016
TB Burden in India
• Incidence: 217(112-355) cases per 100,000 population
• Deaths: 32 (29-35) deaths per 100,000 population
• MDR-TB (Multidrug resistant-TB) in India
–MDR TB among new cases <3% and in Retreatment
cases is 13-17%
–Incidence of MDR/RR TB cases per 100,000: 9.9
• HIV among estimated incident TB patients- 4%
• Affects predominantly economically productive age
group leading to huge socio-economic impact
Global TB Report WHO 2016
MDG6 TB target achieved
TB
REVERSED
Rateper100,000population
50%
But huge burden of deaths and suffering remains in India.
Estimated 28 lakh incident TB cases in 2016, with 4.2 lakh
deaths
>3.5 million
additional
lives saved
since
inception
50%
WHO’s previous estimations of TB burden in India
MDG Target Achievement
TB Prevalence
To reduce prevalence by half
(>50% reduction)
465  195 per lakh pop
(58% reduction)
TB Mortality
To reduce mortality by half
(>50% reduction)
38  17 per lakh pop
(55% reduction)
TB incidence
To halt increase and reverse trend
(>0% reduction)
216  167 per lakh pop
(23% reduction)
2011 workshop, based on information available from
• 7 district level prevalence surveys,
• prevalence of infection based on ARTI survey
• programme notification information
• Expert opinion
• 4 mortality surveys
Global TB Report WHO 2016
WHO’s proposed interim estimates includes, backward
estimation of incidence and mortality from 1990 to 2015
compared with current estimates as below:
Previous estimates Interim estimates
TB Mortality
38  17 per lakh pop
(55% reduction)
76  32 per lakh pop
(4.2 Lakhs)
(58% reduction)
TB incidence
216  167 per lakh pop
(23% reduction)
300  217 per lakh pop
(28 Lakhs)
(28% reduction)
Footnote: These are interim estimates, based on newer evidences &
information available, pending the results of planned National TB
prevalence survey
India Population: 1311 million
Global TB Report WHO 2016
TB Burden
Global
2015
India
2015
Global
2016
India
2016
Incidence
TB
96 lakh 22lakh 104 lakhs 28 Lakhs
Mortality
of TB *
11 lakh 2.2lakh 14 lakhs 4.2 Lakhs
Incidence
HIV TB
12lakh 1.1lakh 11.7
lakhs
1.1 lakhs
Mortality
of HIV-
TB *
3.9 lakh 31,000 3.9 lakhs 37,000
MDR-TB 4. 8 lakh 71,000 5.8 lakhs 130,000
Is TB burden increasing???….
Answer… NO
• WHO estimates TB burden from time to time based on
the best available information from time to time
• WHO’s re-estimation is based on newer evidences &
information available since the previous estimation
since 2011, pending the results of planned National TB
prevalence survey
• TB burden is not increasing & the re-estimation still
suggests declining trend of incidence and mortality.
Rate of TB suspect examined and Total
TB case notification rate
0
100
200
300
400
500
600
700
800
0
20
40
60
80
100
120
140 2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
Perlakhpopulation
perlakhpopulation
Total TB case Notification rate Suspect examined per lakh population
Globally, there was a 4.3 million gap
between incident and notified TB cases
in 2015. India, Indonesia and Nigeria
account for almost half of the missing TB
cases.
TB India Annual Report, GoI 2016
Strategic vision of GoI for TB
Vision: “TB-free India” with zero deaths,
disease and poverty due to TB
Goal : Universal Access to quality TB
diagnosis & treatment for all
pulmonary & extra pulmonary TB
patients including drug resistant and
HIV associated TB
‘To achieve a rapid decline in burden of
TB, morbidity and mortality while
working towards elimination of TB in
India by 2025’.
National Strategic Plan for TB Elimination, GoI 2017-2025
A New Era of Global TB
Monitoring
A New Era of Global TB Monitoring
• The Sustainable Development Goals (SDGs) for 2030 were adopted by the UN in
2015. One of the targets is to end the Global TB epidemic.
• End TB Strategy approved by WHA 2014, has three high level indicators :
– The TB Incidence Rates
– The absolute number of TB deaths
– The percentage of TB patients and their households that experience
catastrophic cost as a result pf TB disease.
• Targets have been defined for these indicators for 2030 and2035, with
accompanying milestones for 2020 and 2025
• The 2020 milestones of the End TB Strategy are a 35% reduction in the absolute
number of TB deaths and a 20% reduction in TB incidence rates, compared with
2015 levels; and that no TB affected household face catastrophic cost
• The strategy calls for 90% reduction in TB deaths and 80% reduction in TB
incidence rates by 2030 compared to 2015 levels
Vision:
A world free of TB
Zero TB deaths,
Zero TB disease, and
Zero TB suffering
Goal:
End the Global TB
epidemic
Vision, goal, targets, milestones
(2,2 million)
(2.2 lakh)
The End TB Strategy:
3 pillars and 4 principles
Global commitment
to End Poverty and to End TB by
2030
Goal 1: End poverty in all its forms everywhere
1.3: Implement nationally appropriate social protection systems
and measures for all, including floors, and by 2030 achieve
substantial coverage of the poor and vulnerable
NSP Planning
Vision Documents for seven year
( 2017 /18 to 2013-24 )
Goal : End the TB epidemic in India by 2030
• Planning preparation will be initiated for
NSP in consultation with all stake holders
• Incorporating newer policy and guidelines
• Experience from implementation of NSP
• Alignment with END-TB strategy
• Resource mapping and mobilization
Available from: http://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf.
Paradigm shift in approach
Medical
Colleges
NGOs
Private
Practitio
ners
Standard
Diagnosis
Standard
Treatmen
t
Public
Health
Responsi
bility
Social
Inclusion
Government is the enabler of the TB
service, not the sole provider
Care of All TB patients as per
Programme guideline
TB Surveillance System,NIKSHAY
(Case Based Web Based TB Notification System)
Public TB
notification
system
DR-TB
lab & RX
centres
Private TB
notification
system
External
projects
Electronic Patient Treatment adherence
support
- 99DOTS low-cost monitoring and improving
medication adherence
99 DOTS Expansion for all PLHIV patients
- Evaluation of other ICT based mechanism for
expansion
Private Sector notification
PPM Intervention- Evaluation
TB notification increased with use of free
drugs and ICT facilitation
Microbiological confirmation can be
increased by providing access to CBNAAT
Engage first and then work to improve
quality
Scalability may require additional resources
Can we afford to lose patients from private
sector?
Public health action
On receipt of information on TB notifications following
actions are to be taken by local public health staff:
• Patient home visit as per convenience of patient,
• Counselling of TB patient and family members,
• Treatment adherence and follow up support ensure
treatment completion,
• Contact tracing, symptoms screening, evaluation of
TB symptomatic and offering INH chemoprophylaxis
to eligible contacts,
• Offering HIV testing, Drug Susceptibility Testing
(DST), if eligible.
Active Case finding
• Identification of high risk and
vulnerable groups
• IEC and Media Campaign for
ACF
• Utilization of more sensitive
tools for diagnosis
• Appropriate linkages for
treatment support
RNTCP culture and DST labs network
( July 2016)
By technology
- Solid culture: 46
- LPA: 52
-Liquid culture: 31
- CB-NAAT: 628
C-DST labs:
65
SL-DST: 25
Strengthening Laboratory services
• Evaluation of laboratory
network
• In-country Second Line
LPA validation study
• Laboratory scale-up
incorporating newer
technologies and
Programme policy
Initial 5 States:
• Himachal
Pradesh
• Sikkim
• Bihar
• Maharashtra
• Kerala
Rollout of Daily Regimen
in 104 districts
Rajas than
Gujarat
Maharas htra
Oriss a
Karnataka
Madhya Prades h
Bihar
Uttar
Pradesh
Jam m u &
Kas hm ir
Tam il Nadu
Assam
Telangana
Chhattis garh
Andhra Pradesh
Jhark hand
Punjab
W est B engal
Kerala
Haryana
Himac hal
Pradesh
Manipur
Mizoram
Andam an & N icobar
Dam an & Diu
Uttarakhand
Sikkim
Arunachal
Pradesh
N aga lan d
Tripura
Whole Country coverage by
end of 2017
BDQ Launch – 21 Mar
16
First patient put on BDQ at DR-TB Center
Guwahati, Assam on 6 June 16
Roll out of BDQ-CAP in 5
states
TB-Diabetes
• National Framework
• Phase wise implementation
in all states
• Supervision and monitoring
Available from:
http://tbcindia.nic.in/WriteReadData/National%20framework%20for%20joint%20TB%20diabe
tes.pdf.
PRAGATI Review
• Consultative meeting
held with states on 22nd
June 2016
• Districts identified
based on agreed criteria
(High TB, TB-HIV,
MDR-TB and low case
finding )
• Development of action
plan for the same in
progress
High Priority Districts
Average
High TB
High TB-HIV
High DR-TB
Very low case finding efforts
High case finding but low TCNR
Metro + Sikkim
INDEX TB Guidelines 2016
• New guidelines developed for
management of Extra pulmonary TB
by Central TB Division , AIIMS, New
Delhi , WHO and GHA (Global
Health Advocates)
• Dissemination Workshop held on
09th July 2016 at AIIMS New Delhi
• Dissemination and further develop
a training module
Available from:
http://www.icmr.nic.in/guidelines/TB/Index-
TB%20Guidelines%20-20green%20colour%202594164.pdf.
Intensified TB case finding and treatment at high burden
Anti-Retroviral Therapy (ART) centres
 Single window service delivery
for TB & HIV
 Intensified case finding
 TB diagnosis through CBNAAT
 Daily Regimen
 Better management of side
effects- Pharmacovigilance
 Use of newer technology for
treatment monitoring
 Isoniazid Preventive Therapy
 Air Borne Infection control
Progress so far
 45419 PLHIV tested for TB
 6389 diagnosed as TB
 185 diagnosed as Rif Resistance
 6073 put on Daily Anti TB
treatment
 149 Rif /R put on CAT IV
Country-wide expansion by 2nd October 2016
Accelerating access to quality TB
diagnosis for paediatric cases
• Daily regimen for pediatric TB
• Collaboration with IAP and TB
Alliance for Pediatric module
Dissemination
• UNITAID Project for Augmenting
TB service for pediatric TB
Other initiatives
• National Drug Resistance NDRS results for policy
formulation
• Approval of Nutritional support guidelines
• Roll-out of shorter regimen for MDR-TB and 2nd line
LPA
• National Prevalence Survey
• Research Consortium
Global TB projections to 2035 compared with current trends
World TB Day , 24th March 2017
• It commemorates the day in 1882 when Dr Robert Koch astounded
the scientific community by announcing his discovery: the cause of
tuberculosis, the TB bacillus
• Koch's discovery opened the way towards diagnosing and curing TB.
• Celebrated each year: Build Public Awareness and Design efforts to
Eliminate the disease.
• On 22 March 2017, WHO issues ethics guidance to protect rights of
TB patients: Patients, Communities, Health workers, policy makers,
other stakeholders
LIVES SAVED
49 MILLION
MDR TB CASES
480000
FUNDING
2BILLION US$ PER YR NEEDED TO FILL THE
RESOURCE GAP
GLOBAL
Thank You
WORLD TB DAY 24TH MARCH 2017

Mais conteúdo relacionado

Mais procurados

EPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSISEPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSISSantosh Yadav
 
EPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSISEPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSISHarivansh Chopra
 
WORLD TUBERCULOSIS DAY 2023 AWARENESS.pptx
WORLD TUBERCULOSIS DAY 2023 AWARENESS.pptxWORLD TUBERCULOSIS DAY 2023 AWARENESS.pptx
WORLD TUBERCULOSIS DAY 2023 AWARENESS.pptxanjalatchi
 
CME NTEP 28-12-2022 Dr Purabi.pdf
CME NTEP 28-12-2022 Dr Purabi.pdfCME NTEP 28-12-2022 Dr Purabi.pdf
CME NTEP 28-12-2022 Dr Purabi.pdfDr Purabi Phukan
 
National Vector Borne Disease Control Programme (NVBDCP)
National Vector Borne Disease Control Programme (NVBDCP)National Vector Borne Disease Control Programme (NVBDCP)
National Vector Borne Disease Control Programme (NVBDCP)Vivek Varat
 
National Tuberculosis Elimination Programme.pptx
National Tuberculosis Elimination Programme.pptxNational Tuberculosis Elimination Programme.pptx
National Tuberculosis Elimination Programme.pptxDarshnaSarvaiya2
 
Recent updates in TB programme
Recent updates in TB programmeRecent updates in TB programme
Recent updates in TB programmeAvantikaGupta33
 
NLEP_Program Management_DLO.pdf
NLEP_Program Management_DLO.pdfNLEP_Program Management_DLO.pdf
NLEP_Program Management_DLO.pdfPhcNelliyampathy
 
Nsp draft 20.02.2017 1
Nsp draft 20.02.2017 1Nsp draft 20.02.2017 1
Nsp draft 20.02.2017 1Wal
 
Programmatic management of drug resistant tuberculosis(pmdt)
Programmatic management of drug resistant tuberculosis(pmdt)Programmatic management of drug resistant tuberculosis(pmdt)
Programmatic management of drug resistant tuberculosis(pmdt)Anisha Mohan
 
epidemiology of Tuberculosis
epidemiology of Tuberculosisepidemiology of Tuberculosis
epidemiology of TuberculosisAbhishek Agarwal
 
Epidemiology of tb with recent advances acknowledged by who
Epidemiology of tb with recent advances acknowledged by whoEpidemiology of tb with recent advances acknowledged by who
Epidemiology of tb with recent advances acknowledged by whoRama shankar
 
National TB Elimination programme(NTEP) at a glance
National TB Elimination programme(NTEP) at a glanceNational TB Elimination programme(NTEP) at a glance
National TB Elimination programme(NTEP) at a glancePROFDRSUSMITAKUNDU
 
Global and Indian plan to End TB
Global and Indian plan to End TBGlobal and Indian plan to End TB
Global and Indian plan to End TBRama shankar
 
Revised definitions of tb cases and management as per ntep
Revised definitions of tb cases and management as per ntepRevised definitions of tb cases and management as per ntep
Revised definitions of tb cases and management as per ntepDrSmritiMadhusikta
 
Rabies - a public health view
Rabies - a public health viewRabies - a public health view
Rabies - a public health viewRizwan S A
 

Mais procurados (20)

EPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSISEPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSIS
 
EPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSISEPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSIS
 
WORLD TUBERCULOSIS DAY 2023 AWARENESS.pptx
WORLD TUBERCULOSIS DAY 2023 AWARENESS.pptxWORLD TUBERCULOSIS DAY 2023 AWARENESS.pptx
WORLD TUBERCULOSIS DAY 2023 AWARENESS.pptx
 
The end tb strategy
The end tb strategy The end tb strategy
The end tb strategy
 
CME NTEP 28-12-2022 Dr Purabi.pdf
CME NTEP 28-12-2022 Dr Purabi.pdfCME NTEP 28-12-2022 Dr Purabi.pdf
CME NTEP 28-12-2022 Dr Purabi.pdf
 
National Vector Borne Disease Control Programme (NVBDCP)
National Vector Borne Disease Control Programme (NVBDCP)National Vector Borne Disease Control Programme (NVBDCP)
National Vector Borne Disease Control Programme (NVBDCP)
 
National Tuberculosis Elimination Programme.pptx
National Tuberculosis Elimination Programme.pptxNational Tuberculosis Elimination Programme.pptx
National Tuberculosis Elimination Programme.pptx
 
Recent updates in TB programme
Recent updates in TB programmeRecent updates in TB programme
Recent updates in TB programme
 
NLEP_Program Management_DLO.pdf
NLEP_Program Management_DLO.pdfNLEP_Program Management_DLO.pdf
NLEP_Program Management_DLO.pdf
 
Nsp draft 20.02.2017 1
Nsp draft 20.02.2017 1Nsp draft 20.02.2017 1
Nsp draft 20.02.2017 1
 
Programmatic management of drug resistant tuberculosis(pmdt)
Programmatic management of drug resistant tuberculosis(pmdt)Programmatic management of drug resistant tuberculosis(pmdt)
Programmatic management of drug resistant tuberculosis(pmdt)
 
epidemiology of Tuberculosis
epidemiology of Tuberculosisepidemiology of Tuberculosis
epidemiology of Tuberculosis
 
Vpd surveillance system
Vpd surveillance systemVpd surveillance system
Vpd surveillance system
 
NTEP By Rajesh Das.pptx
NTEP By Rajesh Das.pptxNTEP By Rajesh Das.pptx
NTEP By Rajesh Das.pptx
 
Epidemiology of tb with recent advances acknowledged by who
Epidemiology of tb with recent advances acknowledged by whoEpidemiology of tb with recent advances acknowledged by who
Epidemiology of tb with recent advances acknowledged by who
 
National TB Elimination programme(NTEP) at a glance
National TB Elimination programme(NTEP) at a glanceNational TB Elimination programme(NTEP) at a glance
National TB Elimination programme(NTEP) at a glance
 
Global and Indian plan to End TB
Global and Indian plan to End TBGlobal and Indian plan to End TB
Global and Indian plan to End TB
 
Revised definitions of tb cases and management as per ntep
Revised definitions of tb cases and management as per ntepRevised definitions of tb cases and management as per ntep
Revised definitions of tb cases and management as per ntep
 
Rabies - a public health view
Rabies - a public health viewRabies - a public health view
Rabies - a public health view
 
Tuberculosis
Tuberculosis Tuberculosis
Tuberculosis
 

Semelhante a Tb recent updates

Tuberculosis National Health Program in Nepal
Tuberculosis National Health Program  in Nepal Tuberculosis National Health Program  in Nepal
Tuberculosis National Health Program in Nepal Public Health
 
tb-2102161hdidmkdijddbndksos85906 (2).pdf
tb-2102161hdidmkdijddbndksos85906 (2).pdftb-2102161hdidmkdijddbndksos85906 (2).pdf
tb-2102161hdidmkdijddbndksos85906 (2).pdfanchalyadav895389
 
critical review_RNTCP1 -
critical review_RNTCP1 -critical review_RNTCP1 -
critical review_RNTCP1 -Isha Porwal
 
Rntcp and national strategic plan(nsp) for tb
Rntcp and national strategic plan(nsp) for tbRntcp and national strategic plan(nsp) for tb
Rntcp and national strategic plan(nsp) for tbWal
 
Revised national tuberculosis control programme
Revised national tuberculosis control programmeRevised national tuberculosis control programme
Revised national tuberculosis control programmeRavi Rohilla
 
National tuberculosis elimination programme [Autosaved].pptx
National tuberculosis elimination programme [Autosaved].pptxNational tuberculosis elimination programme [Autosaved].pptx
National tuberculosis elimination programme [Autosaved].pptxSanaKhader1
 
Towards TB elimination - Giovanni Battista Migliori
Towards TB elimination - Giovanni Battista MiglioriTowards TB elimination - Giovanni Battista Migliori
Towards TB elimination - Giovanni Battista MiglioriWAidid
 
NTP-presentation-2020.pptx
NTP-presentation-2020.pptxNTP-presentation-2020.pptx
NTP-presentation-2020.pptxSani191640
 
Revised national tuberculosis control programme (RNTCP) in India
Revised national tuberculosis control programme (RNTCP) in IndiaRevised national tuberculosis control programme (RNTCP) in India
Revised national tuberculosis control programme (RNTCP) in IndiaKavya .
 
Revised national tuberculosis control programme
Revised national tuberculosis control programmeRevised national tuberculosis control programme
Revised national tuberculosis control programmeMohammed Shafeeqe
 

Semelhante a Tb recent updates (20)

RNTCP
RNTCPRNTCP
RNTCP
 
Tuberculosis National Health Program in Nepal
Tuberculosis National Health Program  in Nepal Tuberculosis National Health Program  in Nepal
Tuberculosis National Health Program in Nepal
 
ntep.pptx
ntep.pptxntep.pptx
ntep.pptx
 
tb-2102161hdidmkdijddbndksos85906 (2).pdf
tb-2102161hdidmkdijddbndksos85906 (2).pdftb-2102161hdidmkdijddbndksos85906 (2).pdf
tb-2102161hdidmkdijddbndksos85906 (2).pdf
 
critical review_RNTCP1 -
critical review_RNTCP1 -critical review_RNTCP1 -
critical review_RNTCP1 -
 
End tb
End tbEnd tb
End tb
 
RNTCP
RNTCPRNTCP
RNTCP
 
Rntcp and national strategic plan(nsp) for tb
Rntcp and national strategic plan(nsp) for tbRntcp and national strategic plan(nsp) for tb
Rntcp and national strategic plan(nsp) for tb
 
newrntcp-160127070415.pdf
newrntcp-160127070415.pdfnewrntcp-160127070415.pdf
newrntcp-160127070415.pdf
 
Revised national tuberculosis control programme
Revised national tuberculosis control programmeRevised national tuberculosis control programme
Revised national tuberculosis control programme
 
Rntcp program
Rntcp programRntcp program
Rntcp program
 
National tuberculosis elimination programme [Autosaved].pptx
National tuberculosis elimination programme [Autosaved].pptxNational tuberculosis elimination programme [Autosaved].pptx
National tuberculosis elimination programme [Autosaved].pptx
 
Dpseea model on tb
Dpseea model on tbDpseea model on tb
Dpseea model on tb
 
RNTCP.pptx
RNTCP.pptxRNTCP.pptx
RNTCP.pptx
 
Towards TB elimination - Giovanni Battista Migliori
Towards TB elimination - Giovanni Battista MiglioriTowards TB elimination - Giovanni Battista Migliori
Towards TB elimination - Giovanni Battista Migliori
 
RNTCP ARPIT.pptx
RNTCP ARPIT.pptxRNTCP ARPIT.pptx
RNTCP ARPIT.pptx
 
NTP-presentation-2020.pptx
NTP-presentation-2020.pptxNTP-presentation-2020.pptx
NTP-presentation-2020.pptx
 
Revised national tuberculosis control programme (RNTCP) in India
Revised national tuberculosis control programme (RNTCP) in IndiaRevised national tuberculosis control programme (RNTCP) in India
Revised national tuberculosis control programme (RNTCP) in India
 
Revised national tuberculosis control programme
Revised national tuberculosis control programmeRevised national tuberculosis control programme
Revised national tuberculosis control programme
 
Global tuberculosis report 2013 supplement
Global tuberculosis report 2013 supplementGlobal tuberculosis report 2013 supplement
Global tuberculosis report 2013 supplement
 

Mais de MADHUR VERMA

#Covid19: Information guide for general Public.
#Covid19: Information guide for general Public.#Covid19: Information guide for general Public.
#Covid19: Information guide for general Public.MADHUR VERMA
 
Aids final 19112017
Aids final 19112017Aids final 19112017
Aids final 19112017MADHUR VERMA
 
Disability and impairment
Disability and impairmentDisability and impairment
Disability and impairmentMADHUR VERMA
 
Ebola virus disease
Ebola virus diseaseEbola virus disease
Ebola virus diseaseMADHUR VERMA
 
qualitative research DR. MADHUR VERMA PGIMS ROHTAK
 qualitative research DR. MADHUR VERMA PGIMS ROHTAK qualitative research DR. MADHUR VERMA PGIMS ROHTAK
qualitative research DR. MADHUR VERMA PGIMS ROHTAKMADHUR VERMA
 
Public health emergencies DR. MADHUR VERMA PGIMS ROHTAK
Public health emergencies DR. MADHUR VERMA PGIMS ROHTAKPublic health emergencies DR. MADHUR VERMA PGIMS ROHTAK
Public health emergencies DR. MADHUR VERMA PGIMS ROHTAKMADHUR VERMA
 
Logical framework approach DR.MADHUR VERMA PGIMS ROHTAK
Logical framework approach DR.MADHUR VERMA PGIMS ROHTAKLogical framework approach DR.MADHUR VERMA PGIMS ROHTAK
Logical framework approach DR.MADHUR VERMA PGIMS ROHTAKMADHUR VERMA
 
Social audit. dr.madhur verma PGIMS ROHTAK
Social audit.  dr.madhur verma PGIMS ROHTAKSocial audit.  dr.madhur verma PGIMS ROHTAK
Social audit. dr.madhur verma PGIMS ROHTAKMADHUR VERMA
 
MATERIALS MANAGEMENT
MATERIALS MANAGEMENTMATERIALS MANAGEMENT
MATERIALS MANAGEMENTMADHUR VERMA
 

Mais de MADHUR VERMA (9)

#Covid19: Information guide for general Public.
#Covid19: Information guide for general Public.#Covid19: Information guide for general Public.
#Covid19: Information guide for general Public.
 
Aids final 19112017
Aids final 19112017Aids final 19112017
Aids final 19112017
 
Disability and impairment
Disability and impairmentDisability and impairment
Disability and impairment
 
Ebola virus disease
Ebola virus diseaseEbola virus disease
Ebola virus disease
 
qualitative research DR. MADHUR VERMA PGIMS ROHTAK
 qualitative research DR. MADHUR VERMA PGIMS ROHTAK qualitative research DR. MADHUR VERMA PGIMS ROHTAK
qualitative research DR. MADHUR VERMA PGIMS ROHTAK
 
Public health emergencies DR. MADHUR VERMA PGIMS ROHTAK
Public health emergencies DR. MADHUR VERMA PGIMS ROHTAKPublic health emergencies DR. MADHUR VERMA PGIMS ROHTAK
Public health emergencies DR. MADHUR VERMA PGIMS ROHTAK
 
Logical framework approach DR.MADHUR VERMA PGIMS ROHTAK
Logical framework approach DR.MADHUR VERMA PGIMS ROHTAKLogical framework approach DR.MADHUR VERMA PGIMS ROHTAK
Logical framework approach DR.MADHUR VERMA PGIMS ROHTAK
 
Social audit. dr.madhur verma PGIMS ROHTAK
Social audit.  dr.madhur verma PGIMS ROHTAKSocial audit.  dr.madhur verma PGIMS ROHTAK
Social audit. dr.madhur verma PGIMS ROHTAK
 
MATERIALS MANAGEMENT
MATERIALS MANAGEMENTMATERIALS MANAGEMENT
MATERIALS MANAGEMENT
 

Último

Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
Screening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxScreening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxtadehabte
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfMyThaoAiDoan
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfDivya Kanojiya
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)MohamadAlhes
 
SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxAbhishek943418
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledgeassessoriafabianodea
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingSakthi Kathiravan
 

Último (20)

Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
Screening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptxScreening for colorectal cancer AAU.pptx
Screening for colorectal cancer AAU.pptx
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdf
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
 
SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptx
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursing
 

Tb recent updates

  • 1. TB Burden Updates: Global and Indian Scenario
  • 2. Countries in the three TB high burden country list Global TB Report WHO 2016
  • 3. TB Burden in India • Incidence: 217(112-355) cases per 100,000 population • Deaths: 32 (29-35) deaths per 100,000 population • MDR-TB (Multidrug resistant-TB) in India –MDR TB among new cases <3% and in Retreatment cases is 13-17% –Incidence of MDR/RR TB cases per 100,000: 9.9 • HIV among estimated incident TB patients- 4% • Affects predominantly economically productive age group leading to huge socio-economic impact Global TB Report WHO 2016
  • 4. MDG6 TB target achieved TB REVERSED Rateper100,000population 50% But huge burden of deaths and suffering remains in India. Estimated 28 lakh incident TB cases in 2016, with 4.2 lakh deaths >3.5 million additional lives saved since inception 50%
  • 5. WHO’s previous estimations of TB burden in India MDG Target Achievement TB Prevalence To reduce prevalence by half (>50% reduction) 465  195 per lakh pop (58% reduction) TB Mortality To reduce mortality by half (>50% reduction) 38  17 per lakh pop (55% reduction) TB incidence To halt increase and reverse trend (>0% reduction) 216  167 per lakh pop (23% reduction) 2011 workshop, based on information available from • 7 district level prevalence surveys, • prevalence of infection based on ARTI survey • programme notification information • Expert opinion • 4 mortality surveys Global TB Report WHO 2016
  • 6. WHO’s proposed interim estimates includes, backward estimation of incidence and mortality from 1990 to 2015 compared with current estimates as below: Previous estimates Interim estimates TB Mortality 38  17 per lakh pop (55% reduction) 76  32 per lakh pop (4.2 Lakhs) (58% reduction) TB incidence 216  167 per lakh pop (23% reduction) 300  217 per lakh pop (28 Lakhs) (28% reduction) Footnote: These are interim estimates, based on newer evidences & information available, pending the results of planned National TB prevalence survey India Population: 1311 million Global TB Report WHO 2016
  • 7. TB Burden Global 2015 India 2015 Global 2016 India 2016 Incidence TB 96 lakh 22lakh 104 lakhs 28 Lakhs Mortality of TB * 11 lakh 2.2lakh 14 lakhs 4.2 Lakhs Incidence HIV TB 12lakh 1.1lakh 11.7 lakhs 1.1 lakhs Mortality of HIV- TB * 3.9 lakh 31,000 3.9 lakhs 37,000 MDR-TB 4. 8 lakh 71,000 5.8 lakhs 130,000
  • 8. Is TB burden increasing???…. Answer… NO • WHO estimates TB burden from time to time based on the best available information from time to time • WHO’s re-estimation is based on newer evidences & information available since the previous estimation since 2011, pending the results of planned National TB prevalence survey • TB burden is not increasing & the re-estimation still suggests declining trend of incidence and mortality.
  • 9. Rate of TB suspect examined and Total TB case notification rate 0 100 200 300 400 500 600 700 800 0 20 40 60 80 100 120 140 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Perlakhpopulation perlakhpopulation Total TB case Notification rate Suspect examined per lakh population Globally, there was a 4.3 million gap between incident and notified TB cases in 2015. India, Indonesia and Nigeria account for almost half of the missing TB cases. TB India Annual Report, GoI 2016
  • 10. Strategic vision of GoI for TB Vision: “TB-free India” with zero deaths, disease and poverty due to TB Goal : Universal Access to quality TB diagnosis & treatment for all pulmonary & extra pulmonary TB patients including drug resistant and HIV associated TB ‘To achieve a rapid decline in burden of TB, morbidity and mortality while working towards elimination of TB in India by 2025’. National Strategic Plan for TB Elimination, GoI 2017-2025
  • 11.
  • 12.
  • 13. A New Era of Global TB Monitoring
  • 14. A New Era of Global TB Monitoring • The Sustainable Development Goals (SDGs) for 2030 were adopted by the UN in 2015. One of the targets is to end the Global TB epidemic. • End TB Strategy approved by WHA 2014, has three high level indicators : – The TB Incidence Rates – The absolute number of TB deaths – The percentage of TB patients and their households that experience catastrophic cost as a result pf TB disease. • Targets have been defined for these indicators for 2030 and2035, with accompanying milestones for 2020 and 2025 • The 2020 milestones of the End TB Strategy are a 35% reduction in the absolute number of TB deaths and a 20% reduction in TB incidence rates, compared with 2015 levels; and that no TB affected household face catastrophic cost • The strategy calls for 90% reduction in TB deaths and 80% reduction in TB incidence rates by 2030 compared to 2015 levels
  • 15.
  • 16. Vision: A world free of TB Zero TB deaths, Zero TB disease, and Zero TB suffering Goal: End the Global TB epidemic Vision, goal, targets, milestones (2,2 million) (2.2 lakh)
  • 17. The End TB Strategy: 3 pillars and 4 principles
  • 18.
  • 19.
  • 20.
  • 21.
  • 22. Global commitment to End Poverty and to End TB by 2030 Goal 1: End poverty in all its forms everywhere 1.3: Implement nationally appropriate social protection systems and measures for all, including floors, and by 2030 achieve substantial coverage of the poor and vulnerable
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29. NSP Planning Vision Documents for seven year ( 2017 /18 to 2013-24 ) Goal : End the TB epidemic in India by 2030 • Planning preparation will be initiated for NSP in consultation with all stake holders • Incorporating newer policy and guidelines • Experience from implementation of NSP • Alignment with END-TB strategy • Resource mapping and mobilization Available from: http://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf.
  • 30. Paradigm shift in approach Medical Colleges NGOs Private Practitio ners Standard Diagnosis Standard Treatmen t Public Health Responsi bility Social Inclusion Government is the enabler of the TB service, not the sole provider Care of All TB patients as per Programme guideline
  • 31. TB Surveillance System,NIKSHAY (Case Based Web Based TB Notification System) Public TB notification system DR-TB lab & RX centres Private TB notification system External projects
  • 32. Electronic Patient Treatment adherence support - 99DOTS low-cost monitoring and improving medication adherence 99 DOTS Expansion for all PLHIV patients - Evaluation of other ICT based mechanism for expansion
  • 34. PPM Intervention- Evaluation TB notification increased with use of free drugs and ICT facilitation Microbiological confirmation can be increased by providing access to CBNAAT Engage first and then work to improve quality Scalability may require additional resources Can we afford to lose patients from private sector?
  • 35. Public health action On receipt of information on TB notifications following actions are to be taken by local public health staff: • Patient home visit as per convenience of patient, • Counselling of TB patient and family members, • Treatment adherence and follow up support ensure treatment completion, • Contact tracing, symptoms screening, evaluation of TB symptomatic and offering INH chemoprophylaxis to eligible contacts, • Offering HIV testing, Drug Susceptibility Testing (DST), if eligible.
  • 36. Active Case finding • Identification of high risk and vulnerable groups • IEC and Media Campaign for ACF • Utilization of more sensitive tools for diagnosis • Appropriate linkages for treatment support
  • 37. RNTCP culture and DST labs network ( July 2016) By technology - Solid culture: 46 - LPA: 52 -Liquid culture: 31 - CB-NAAT: 628 C-DST labs: 65 SL-DST: 25
  • 38. Strengthening Laboratory services • Evaluation of laboratory network • In-country Second Line LPA validation study • Laboratory scale-up incorporating newer technologies and Programme policy
  • 39. Initial 5 States: • Himachal Pradesh • Sikkim • Bihar • Maharashtra • Kerala Rollout of Daily Regimen in 104 districts Rajas than Gujarat Maharas htra Oriss a Karnataka Madhya Prades h Bihar Uttar Pradesh Jam m u & Kas hm ir Tam il Nadu Assam Telangana Chhattis garh Andhra Pradesh Jhark hand Punjab W est B engal Kerala Haryana Himac hal Pradesh Manipur Mizoram Andam an & N icobar Dam an & Diu Uttarakhand Sikkim Arunachal Pradesh N aga lan d Tripura Whole Country coverage by end of 2017
  • 40. BDQ Launch – 21 Mar 16 First patient put on BDQ at DR-TB Center Guwahati, Assam on 6 June 16 Roll out of BDQ-CAP in 5 states
  • 41. TB-Diabetes • National Framework • Phase wise implementation in all states • Supervision and monitoring Available from: http://tbcindia.nic.in/WriteReadData/National%20framework%20for%20joint%20TB%20diabe tes.pdf.
  • 42. PRAGATI Review • Consultative meeting held with states on 22nd June 2016 • Districts identified based on agreed criteria (High TB, TB-HIV, MDR-TB and low case finding ) • Development of action plan for the same in progress
  • 43. High Priority Districts Average High TB High TB-HIV High DR-TB Very low case finding efforts High case finding but low TCNR Metro + Sikkim
  • 44. INDEX TB Guidelines 2016 • New guidelines developed for management of Extra pulmonary TB by Central TB Division , AIIMS, New Delhi , WHO and GHA (Global Health Advocates) • Dissemination Workshop held on 09th July 2016 at AIIMS New Delhi • Dissemination and further develop a training module Available from: http://www.icmr.nic.in/guidelines/TB/Index- TB%20Guidelines%20-20green%20colour%202594164.pdf.
  • 45. Intensified TB case finding and treatment at high burden Anti-Retroviral Therapy (ART) centres  Single window service delivery for TB & HIV  Intensified case finding  TB diagnosis through CBNAAT  Daily Regimen  Better management of side effects- Pharmacovigilance  Use of newer technology for treatment monitoring  Isoniazid Preventive Therapy  Air Borne Infection control Progress so far  45419 PLHIV tested for TB  6389 diagnosed as TB  185 diagnosed as Rif Resistance  6073 put on Daily Anti TB treatment  149 Rif /R put on CAT IV Country-wide expansion by 2nd October 2016
  • 46. Accelerating access to quality TB diagnosis for paediatric cases • Daily regimen for pediatric TB • Collaboration with IAP and TB Alliance for Pediatric module Dissemination • UNITAID Project for Augmenting TB service for pediatric TB
  • 47. Other initiatives • National Drug Resistance NDRS results for policy formulation • Approval of Nutritional support guidelines • Roll-out of shorter regimen for MDR-TB and 2nd line LPA • National Prevalence Survey • Research Consortium
  • 48. Global TB projections to 2035 compared with current trends
  • 49. World TB Day , 24th March 2017 • It commemorates the day in 1882 when Dr Robert Koch astounded the scientific community by announcing his discovery: the cause of tuberculosis, the TB bacillus • Koch's discovery opened the way towards diagnosing and curing TB. • Celebrated each year: Build Public Awareness and Design efforts to Eliminate the disease. • On 22 March 2017, WHO issues ethics guidance to protect rights of TB patients: Patients, Communities, Health workers, policy makers, other stakeholders LIVES SAVED 49 MILLION MDR TB CASES 480000 FUNDING 2BILLION US$ PER YR NEEDED TO FILL THE RESOURCE GAP GLOBAL
  • 50. Thank You WORLD TB DAY 24TH MARCH 2017

Notas do Editor

  1. Label for case notification, merge two slides, and interpretation , PPT software for merger
  2. We have to now move towards new era of SDG and from STOP TB Strategy to END TB Strategy. Everyone with TB should have access to the innovative tools and services they need for rapid diagnosis, treatment and care. This is a matter of social justice, fundamental to our goal of universal health coverage. Given the prevalence of drug-resistant tuberculosis, ensuring high quality and complete care will also benefit global health security.
  3. With dr.raghu
  4. There is now a paradigm shift in approach. Earlier, engagements were based on Referral of TB patients for any services (diagnosis, treatment, public health services) to RNTCP. Now – focus is on Quality of care, every patient should get quality acre as per STCI, wherever they get service from, the programme role is facilitatory, focus on surveillance and necessary patient support.
  5. Tolls for notificaiton and NIKSHAY
  6. UATBC – PPM interventions in Mehsana, Patna and Mumbai. Objectives – increase TB notification by offering free drugs and ICT based support. Additionally, encourage microbiological confirmation, extend public health services and report treatment outcome are carried out. Duration – 2 years Results – Increase in TB notification substantially (2-3 times) at all three sites. Microbiological confirmation improved in private sector (30% in Patna and 40% in Mumbai). Adherence support and other public health services are provided. Treatment outcomes are 72%.
  7. One most important aspect of TB notification is to ensure pubic health support for the patients notified by private sector this includes - Patient home visit as per convenience of patient, Counselling of TB patient and family members, Treatment adherence and follow up support ensure treatment completion, Contact tracing, symptoms screening, evaluation of TB symptomatic and offering INH chemoprophylaxis to eligible contacts, Offering HIV testing, Drug Susceptibility Testing (DST), if eligible. This ensure value addition by public health system to patient care in private sector and if done properly, has a huge potential to develop trust which is a pre-requisite for partnership much required for TB control.
  8. Thning for CB NAAT, Laboroatry evaluation, Validation of SLDLPA,Lab scale-up plan for DST guidelines LED FM installation EQA visits of IRL to district NRL visit to states 15 LC upgradation CB NAAT utilization as per RNTCP policy
  9. Photo of launch, guidelines and way forward, few line
  10. Accelerating access to quality TB diagnosis for paediatric cases has three major components Providing CBNAAT machines Linkages for specimen collection Involvement of paediatrician. With this we are able to diagnose more paediatric cases. This project was started in 4 cities , now has been expanded to five additional cities.
  11. Images from each of the activites
  12. Intensify research and development is one of the core component of END TB strategy, it plays a crucial role accelerating reduction in TB incidence and mortality to reach to goal of END TB Strategy. Diagnostic technology , new diagnostic techniques like GeneXpert Omni , New Drugs like Bedaquiline, Delaminide, and few other drugs which in pipeline. The vaccine also needs to be developed for achieving the goal. Finance: Funding for TB control epidemic needs to be increased in view of achieving the goal of END TB .